Legal & General Group
TARO

Legal & General Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Legal & General Group’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,668
Closed -$367K – 3554
2024
Q1 		$367K Hold
8,668
– – ﹤0.01% 2545
2023
Q4 		$362K Buy
8,668
+400
+5% +$14.7K ﹤0.01% 2570
2023
Q3 		$312K Sell
8,268
-105
-1% -$3.94K ﹤0.01% 2617
2023
Q2 		$318K Buy
8,373
+1,641
+24% +$51.5K ﹤0.01% 2615
2023
Q1 		$164K Hold
6,732
– – ﹤0.01% 2653
2022
Q4 		$195K Buy
6,732
+339
+5% +$10.1K ﹤0.01% 2614
2022
Q3 		$192K Sell
6,393
-40
-0.6% -$1.38K ﹤0.01% 2649
2022
Q2 		$233K Sell
6,433
-490
-7% -$18.7K ﹤0.01% 2576
2022
Q1 		$299K Buy
6,923
+1,464
+27% +$68.4K ﹤0.01% 2541
2021
Q4 		$274K Sell
5,459
-56
-1% -$3.14K ﹤0.01% 2591
2021
Q3 		$351K Buy
5,515
+50
+0.9% +$3.46K ﹤0.01% 2522
2021
Q2 		$394K Sell
5,465
-55
-1% -$4.04K ﹤0.01% 2382
2021
Q1 		$407K Sell
5,520
-58
-1% -$4.4K ﹤0.01% 2330
2020
Q4 		$410K Buy
5,578
+634
+13% +$40.8K ﹤0.01% 2296
2020
Q3 		$271K Sell
4,944
-9
-0.2% -$560 ﹤0.01% 2311
2020
Q2 		$329K Hold
4,953
– – ﹤0.01% 2262
2020
Q1 		$303K Hold
4,953
– – ﹤0.01% 2193
2019
Q4 		$436K Sell
4,953
-473
-9% -$39.9K ﹤0.01% 2243
2019
Q3 		$409K Hold
5,426
– – ﹤0.01% 2198
2019
Q2 		$463K Hold
5,426
– – ﹤0.01% 2162
2019
Q1 		$586K Buy
5,426
+496
+10% +$49.4K ﹤0.01% 2121
2018
Q4 		$417K Buy
4,930
+1,862
+61% +$179K ﹤0.01% 2157
2018
Q3 		$302K Hold
3,068
– – ﹤0.01% 2245
2018
Q2 		$355K Sell
3,068
-353
-10% -$38.8K ﹤0.01% 2183
2018
Q1 		$338K Buy
3,421
+81
+2% +$8.21K ﹤0.01% 2204
2017
Q4 		$350K Sell
3,340
-6,571
-66% -$722K ﹤0.01% 2176
2017
Q3 		$1.12M Buy
9,911
+1,593
+19% +$173K ﹤0.01% 1824
2017
Q2 		$932K Buy
8,318
+370
+5% +$41.8K ﹤0.01% 1850
2017
Q1 		$927K Buy
7,948
+131
+2% +$14.5K ﹤0.01% 1824
2016
Q4 		$823K Buy
+7,817
New +$819K ﹤0.01% 1819

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Legal & General Group's TARO Position: Q2 2024 in Review

Legal & General Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 8,668 shares — an estimated $367K sold.

Legal & General Group first reported a position in TARO in Q4 2016 and held it in 30 quarters. The position peaked at $1.12M in Q3 2017. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • Legal & General Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 8,668 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $367K.
  • Legal & General Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2016 and held it in 30 quarters.
  • Legal & General Group's Taro Pharmaceutical Industries Ltd. position peaked at $1.12M in Q3 2017.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.